AstraZeneca highlights broad oncology portfolio at ESMO conference
read at STAT ↗Positive
At the European Society for Medical Oncology (ESMO) meeting in Madrid, AstraZeneca used the platform to showcase its cancer research.
The company presented data on both established medicines and newer candidates, with four of the twelve presidential-session slots featuring its drugs.
AstraZeneca’s cancer R&D head, Susan Galbraith, said the presentations demonstrate the breadth and depth of the portfolio and the quality of the data.
The emphasis on novel drug combinations and a potential next-generation targeted chemotherapy suggests the firm is aiming to expand its oncology pipeline.
source
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: At ESMO, AstraZeneca’s cancer pursuits get a showcase”
read at STAT ↗463 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that